Filing Details

Accession Number:
0001493152-22-035184
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-12 16:22:59
Reporting Period:
2022-12-09
Accepted Time:
2022-12-12 16:22:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1174940 Oragenics Inc OGEN Pharmaceutical Preparations (2834) 593410522
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1234880 C Robert Koski 4902 Eisenhower Boulevard
Tampa FL 33634
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-12-09 48,795 $0.20 1,314,652 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 53,086 Indirect See footnote
Common Stock 212,839 Direct
Footnotes
  1. The price reported in Column 4 was the weighted average price on the Transaction Date indicated. The shares were sold in multiple transactions ranging from $0.1750 to $0.2000 on the Transaction Date. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  2. Represents shares owned by the Koski Family Limited Partnership ("KFLP"). The reporting person serves as one of the general partners of the KFLP and disclaims beneficial ownership of the securities reflected as held by the KFLP except to the extent of the reporting person's pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.
  3. Shares owned by trusts of which Mr. Robert C. Koski is sole trustee. Such trusts are as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (10,760 shares); the Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (10,760 shares); the Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (10,000 shares); the Robert Clayton Koski Trust for the benefit of Robert Edward Koski (10,760 shares); and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (10,806 shares). Mr. Koski disclaims beneficial ownership of the shares held by the trusts except to the extent of any pecuniary interest.
  4. Shares owned directly by Robert C. Koski, a director of the Company.